Qlife Holding AB (publ)

Stockholm Stock Exchange QLIFE.ST

Qlife Holding AB (publ) Price to Earnings Ratio (P/E) on January 14, 2025: -0.08

Qlife Holding AB (publ) Price to Earnings Ratio (P/E) is -0.08 on January 14, 2025, a -84,380.00% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Qlife Holding AB (publ) 52-week high Price to Earnings Ratio (P/E) is -0.00 on June 28, 2024, which is 99.96% above the current Price to Earnings Ratio (P/E).
Qlife Holding AB (publ) 52-week low Price to Earnings Ratio (P/E) is -0.14 on September 05, 2024, which is -69.46% below the current Price to Earnings Ratio (P/E).
Qlife Holding AB (publ) average Price to Earnings Ratio (P/E) for the last 52 weeks is -0.06.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Stockholm Stock Exchange: QLIFE.ST

Qlife Holding AB (publ)

CEO	Mr. Thomas Warthoe
IPO Date	March 2, 2020
Location	Sweden
Headquarters	Redaregatan 48
Employees	24
Sector	Health Care
Industries Pharmaceuticals Biotechnology Medical Instruments

Description

Qlife Holding AB (publ), a med-tech company, manufactures and sells in-vitro diagnostic analyzers and reagents. The company offers Egoo.Health Platform, an integrated platform with a measuring instrument with disposable capsules and software, where each capsule contains a test for a specific biomarker or virus. Its biomarkers include C-reactive protein home-testing capsule, PHE/Phenylalanine for PKU patients, and Sars-CoV-2/Influenza multiplex for virus/bacteria tests. The company was incorporated in 2019 and is based in Helsingborg, Sweden.

Key trends

Past 5 years